poisar

Stocks · News reference

Takeda Launches ORZEYFUL™ (oveporexton) for Narcolepsy Type 1 in the United States

Fiscal.ai

Takeda has announced the U.S. launch of ORZEYFUL™ (oveporexton), a new treatment for adults with narcolepsy type 1.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAmerican Academy Of Sleep Medicine

    AASM releases roadmap to improve women’s sleep health

    The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.

  2. Zacks Investment ResearchNa

    HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

    Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.

  3. Zacks Investment ResearchZacks.Com

    DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

    Denali Therapeutics (DNLI) shares gained 7.8% after reporting Q3 results that beat expectations, with Avlayah revenues reaching $17.8 million and nearly fivefold growth from the previous quarter. The company expects Q4 revenues between $30-32 million and plans multiple 2027 pipeline readouts including an accelerated approval filing for zafinofusp alfa. Despite strong commercial uptake and $1.01 billion in cash, the stock carries a Zacks Rank #3 (Hold) rating due to pipeline setbacks and the loss of Takeda as a partner.